Pharmaceuticals

Johnson & Johnson

Nanobiotix Reports 85.7% Response Rate for JNJ-1900 in Lung Cancer Trial Phase II

Leerink Partners Raises Johnson & Johnson's Rating and Price Target

Johnson & Johnson to Present Multiple Hematology Abstracts at European Hematology Association Congress

Johnson & Johnson Launches Shockwave™ C2 Aero Coronary IVL Catheter

Kepler Cheuvreux Suisse SA Increases Stake in Johnson & Johnson

Johnson & Johnson to Present New Clinical Data at Upcoming Psychiatry Conference

NewEdge Wealth LLC Increased Johnson & Johnson Shares in Q4

S Bank Fund Management Ltd reduced holding of Johnson & Johnson

Johnson & Johnson's STELARA Approved by FDA for Pediatric Crohn's Disease

Johnson & Johnson's TREMFYA® Shows Efficacy in Perianal Fistulizing Crohn's Disease

JNJ-4804 Shows Potential in Treating Refractory Inflammatory Bowel Disease

Johnson & Johnson announces OTTAVA robotic surgery system meets study goals and plans to submit FDA application

Johnson & Johnson's IMPACT Trial for Impella 5.5 Heart Pump in High-Risk Heart Surgery Patients Shows Promising Results

Johnson & Johnson Announces Superior Efficacy of CAPLYTA in Treatment-Resistant Depression

Wealthfront Advisers LLC increases stake in Johnson & Johnson

Johnson & Johnson Halts CAR-T Research Programs for Large B-Cell Lymphoma

Goldman Sachs Maintains Buy Rating on Johnson & Johnson with a Price Target of $275

Johnson & Johnson Showcases Over 20 Oncology Studies at ASCO 2026

Calamos Advisors LLC Increases Stake in Johnson & Johnson

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

Ordinary dividend (cash)

Ex Date: 2026.05.26 (EST), Cash dividend 1.34 USD

Johnson & Johnson (JNJ.US) Q1 2026 Earnings Conference Call

Johnson & Johnson (JNJ.US) Q4 2025 Earnings Conference Call

Johnson & Johnson (JNJ.US) Q3 2025 Earnings Conference Call

Johnson & Johnson (JNJ.US) Q2 2025 Earnings Conference Call

Johnson & Johnson (JNJ.US) Q1 2025 Earnings Conference Call

Johnson & Johnson (JNJ.US) Q4 2024 Earnings Conference Call

The US Supreme Court denied petitions from six major pharmaceutical companies, including AstraZeneca and Johnson & Johnson, challenging the legality of the 'Drug Price Negotiation Program' under the Inflation Reduction Act of 2022. The companies did not comment on the decision. The stock price is currently at 183.25, with a change of +1.67 (+0.92%).

Fidelity

AstraZeneca

iShares US Pharma

Health Care Select Sector SPDR

VG Health

iShares Global Healthcare

AstraZeneca PLC

NOVARTIS AG

Novo Nordisk AS

Bristol Myers Squibb

Novartis AG

Bristol-Myers Squibb Company

Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

SBIO

The US Supreme Court has rejected appeals from major drugmakers against a Medicare program that allows price negotiations for certain drugs, expected to save billions for taxpayers. The decision upholds lower court rulings and follows the 2022 Inflation Reduction Act. Drug companies argue the program violates their rights, but courts have ruled participation in Medicare is voluntary. The first round of negotiations is projected to save $6 billion for the government and reduce costs for seniors.

Yahoo Finance

Merck

ProShares Ultra Health Care ETF

Direxion Pharma & Medical Bull 3X

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Supreme Court rejects big pharma appeals challenging negotiated drug prices in Medicare

NBTX

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer | NBTX Stock News

StockTitan

Nanobiotix SA

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer | NBTX Stock News

DOCS

This week, notable analyst calls included Dell downgraded to Neutral by UBS due to AI server demand being priced in, while J&J was upgraded to Outperform by Leerink Partners on growth prospects from new products. Akamai was upgraded to Buy by BofA, citing its shift to AI infrastructure. AMD was downgraded by Daiwa as recent price rises may moderate. Doximity and Goodyear were also downgraded due to disappointing guidance and raw material pricing issues, respectively.

- Wall Street’s major market averages declined on Friday due to falling tech stocks and rising U.S. Treasury yields after the U.S.-China summit.  
- Analysts issued several upgrades and downgrades, with Dell being downgraded by UBS, which noted that AI server demand is "largely priced in."  
- The overall market sentiment reflected cautious trading as investors reacted to economic signals and analyst recommendations.

Doximity

Akamai Tech

GraniteShares 2x Long DELL Daily ETF

First Trust Nasdaq Food & Semicon

Invesco PHLX Semiconductor ETF

SPDR S&P Semicon

iShares Semiconductor ETF

VanEck Semiconductor ETF

SPDR S&P Health Equip

iShares US Medical Devices

GraniteShares 2x Long AMD Daily ETF

Direxion Semicon Bull 3X

Global X HealthTech ETF

Invesco Semiconductors ETF

Direxion Daily AMD Bull 2X Shares

Dell Tech

UBS Group AG

Notable analyst calls this week: Dell, J&J and AMD stocks among top picks

AMJ Financial Wealth Management increased its holdings in Johnson & Johnson (NYSE: JNJ) by 832.4% during Q4, acquiring an additional 5,427 shares, bringing its total to 6,079 shares valued at $78,000. Other institutional investors also increased their stakes, with 69.55% of the stock owned by institutions. Johnson & Johnson's recent earnings report showed a revenue increase of 9.9% year-over-year, and the company announced a quarterly dividend increase to $1.34 per share.

Market Beat

AMJ Financial Wealth Management Acquires 5,427 Shares of Johnson & Johnson $JNJ

Johnson & Johnson (JNJ) stock has risen 11% year-to-date, outperforming the struggling S&P 500. The company reported record revenue, surpassing $100 billion for the first time, and maintains a 64-year dividend streak. Analysts remain bullish, with a consensus price target of $257, citing strong performance in MedTech and a diversified business model that mitigates risks. Recent upgrades from analysts reflect confidence in JNJ's growth potential and strategic plans, including a spin-off of its Ortho business in 2027.

- Johnson & Johnson (NYSE:JNJ) has performed well in 2026, reporting an 11% year-to-date increase and exceeding revenue estimates, while the S&P 500 struggles.  
- Analysts maintain a bullish outlook, attributing favorable conditions to JNJ's diverse revenue streams and consistent dividend increases, despite ongoing legal challenges and market competition.  
- The company’s focus on oncology and MedTech, coupled with a strong historical performance, positions JNJ as a stable investment choice for both income and growth-focused investors.

Johnson & Johnson(JNJ.US)

Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

Supreme Court rejects big pharma appeals challenging negotiated drug prices in Medicare

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer | NBTX Stock News

Notable analyst calls this week: Dell, J&J and AMD stocks among top picks

AMJ Financial Wealth Management Acquires 5,427 Shares of Johnson & Johnson $JNJ

One Blue-Chip Stock Is Up 11% While the S&P 500 Struggles

Trending